Strengths and Limitations
weight loss
RECRUITMENT
The BARI-OPTIMISE trial has several strengths. Prior to recruitment, patients had undergone a multidisciplinary assessment for additional contributors to poor weight loss. The study was randomized, placebo-controlled, and double-blinded and included comprehensive assessment of body composition, cardiometabolic risk factors, physical function, and health-related quality of life.Our study also had limitations. We only recruited patients following primary surgery; however, a recent retrospective study reported that liraglutide, 3.0 mg, was equally effective for management of poor weight loss after primary or revisional metabolic surgery.Newer gut hormone–based therapies with greater efficacy than liraglutide, 3.0 mg, are emerging.